# A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT

> **NCT00460421** · PHASE1 · COMPLETED · sponsor: **Swedish Orphan Biovitrum** · enrollment: 27 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Palifermin
- **RADIATION:** Total Body irradiation
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT00460421
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2014-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00460421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00460421, "A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00460421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*